1,215
Views
2
CrossRef citations to date
0
Altmetric
Review

Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy

, , , , , , , & show all
Pages 475-489 | Received 12 Nov 2017, Accepted 26 Apr 2018, Published online: 10 May 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Maria J. Bueno & Miguel Quintela-Fandino. (2020) Emerging role of Fatty acid synthase in tumor initiation: implications for cancer prevention. Molecular & Cellular Oncology 7:2.
Read now
Giorgia Cioccoloni, Angelo Aquino, Maria Notarnicola, Maria Gabriella Caruso, Enzo Bonmassar, Manuela Zonfrillo, Simona Caporali, Isabella Faraoni, Cristina Villivà, Maria Pia Fuggetta & Ornella Franzese. (2020) Fatty acid synthase inhibitor orlistat impairs cell growth and down-regulates PD-L1 expression of a human T-cell leukemia line. Journal of Chemotherapy 32:1, pages 30-40.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.